Loading...

Kian Kani, PhD

TitleAssistant Professor of Research Medicine
InstitutionUniversity of Southern California
DepartmentProvost - Ellison Institute
AddressCSC 2250 Alcazar St. Ste. 240
Off Campus
Los Angeles CA 90089
Phone+1 323 442 2539
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1992Thomas Cook Rewards and Recognition Award
    University of Hartford1994Gengras Academic Scholarship
    University of Hartford1996Summa Cum Laude
    Department of Biological Chemistry, UCLA2003David Sigman Award
    Human Proteome Organization2008Outstanding Poster Award
    European Molecular Biology Organization2009Travel Award

    Collapse Overview 
    Collapse Overview
    Cancer has been traditionally classified based on the organ site of origin; breast cancer is different from prostate cancer which is distinct from lung cancer and so on. Over the past several years however, cancer research has introduced reclassification of tumors based on the signaling pathway(s) that causes malignant transformation. As a result, medical oncologists can prescribe drugs that specifically target the aberrant signaling pathway irrespective of the location of the tumor.

    Modern cancer therapeutics have therefore become “targeted” rather than “systemic.” This has brought upon a significant paradigm shift in medical treatment decisions and spurred oncology research to identify biomarkers indicative of signaling pathway activation. The Kani research group utilizes state-of-the-art proteomic techniques in order to identify and characterize novel cancer biomarkers. Our work focuses on the androgen receptor and human epidermal growth factor receptor signaling axes in prostate, lung, breast, ovarian, and pancreatic cancers. Our goal is to enhance patient outcome by empowering medical oncologist with tools and knowledge necessary for personalized medicine.


    Collapse ORNG Applications 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tiemann K, Garri C, Wang J, Clarke L, Kani K. Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays. J Vis Exp. 2018 Sep 19; (139). PMID: 30295648.
      View in: PubMed
    2. Garri C, Howell S, Tiemann K, Tiffany A, Jalali-Yazdi F, Alba MM, Katz JE, Takahashi TT, Landgraf R, Gross ME, Roberts RW, Kani K. Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 2018 Jun 08; 9(44):27363-27379. PMID: 29937991.
      View in: PubMed
    3. Hughes NP, Xu L, Nielsen CH, Chang E, Hori SS, Natarajan A, Lee S, Kjær A, Kani K, Wang SX, Mallick P, Gambhir SS. A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomark. 2018 Apr 13. PMID: 29689709.
      View in: PubMed
    4. Poon C, Chowdhuri S, Kuo CH, Fang Y, Alenghat FJ, Hyatt D, Kani K, Gross ME, Chung EJ. Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. ACS Biomater Sci Eng. 2017 Dec 11; 3(12):3273-3282. PMID: 29302619.
      View in: PubMed
    5. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther. 2017 Aug; 16(8):1645-1657. PMID: 28566434.
      View in: PubMed
    6. Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 Apr; 24(4):157-170. PMID: 28264911.
      View in: PubMed
    7. Kani K. Quantitative Proteomics Using SILAC. Methods Mol Biol. 2017; 1550:171-184. PMID: 28188530.
      View in: PubMed
    8. Frieboes HB, Curtis LT, Wu M, Kani K, Mallick P. Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor. Cancer Inform. 2015; 14:163-75. PMID: 26715830; PMCID: PMC4687979.
    9. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct; 30(10):918-20. PMID: 23051804; PMCID: PMC3471674.
    10. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. PMID: 22911164.
      View in: PubMed
    11. Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13237-42. PMID: 22733765; PMCID: PMC3421218.
    12. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. PMID: 22411897; PMCID: PMC3959865.
    13. Kani K, Sordella R, Mallick P. Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays. Methods Mol Biol. 2012; 795:233-53. PMID: 21960227.
      View in: PubMed
    14. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. PMID: 21829587; PMCID: PMC3146523.
    15. Vogelsang MS, Kani K, Katz JE, Mallick P. Model-based discovery of circulating biomarkers. Methods Mol Biol. 2011; 728:87-107. PMID: 21468942.
      View in: PubMed
    16. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. PMID: 18707148; PMCID: PMC4673049.
    17. Warren CM, Kani K, Landgraf R. The N-terminal domains of neuregulin 1 confer signal attenuation. J Biol Chem. 2006 Sep 15; 281(37):27306-16. PMID: 16825199.
      View in: PubMed
    18. Kani K, Park E, Landgraf R. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry. 2005 Dec 06; 44(48):15842-57. PMID: 16313187.
      View in: PubMed
    19. Kani K, Warren CM, Kaddis CS, Loo JA, Landgraf R. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. J Biol Chem. 2005 Mar 04; 280(9):8238-47. PMID: 15611073.
      View in: PubMed
    Kian's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _